This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants.
Has histologically- or cytologically-confirmed diagnosis of Stage IV squamous or nonsquamous NSCLC
Has measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1
Has an active autoimmune disease that has required systemic treatment in the past 2 years
Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
Has an active infection requiring systemic therapy
Merck Sharp & Dohme LLC
Lead sponsor
Daiichi Sankyo
Collaborator